A vaccine is developed using spike protein of COVID-19 by former NASA engineer

A vaccine is developed using spike protein of COVID-19 by former NASA engineer

A vaccine is developed using spike protein of COVID-19 by former NASA engineer. Image Courtesy – ThePrint

Odin, the institute led by Josiah Zayner, PhD, Former NASA Engineer, began research on the COVID-19 vaccine. The institute conducts research on genetic engineering. The Odin is also the inventor of various technologies of biohacking.

The former NASA engineer also has extensive research on ‘Crisper Gene’ technology. Josiah said he decided to start his own vaccine research after seeing a report on a clinical trial of a DNA vaccine in a research paper at Harvard University. He started making corona vaccine with DNA technology. However, his method is different from other universities.

Josiah Zayner was an engineer at NASA’s Space Synthetic Biology Research Center. Later he left NASA to form his own company and began researching on genetic engineering. The company started with four employees at first. Experimental application of various methods of biohacking began in this organization.

Zayner’s ‘Crisper Kit’ campaign once aroused quite a response. Zayner had a microbiome transplant all over his body in 2016. From that time, he was known as a biohacker. George Church, a professor of genetics at Harvard Medical School, is the Business and Science Advisor to the Odin institute.

Read: COVID-19 medicine found in the extract of Neem Bark, scientists said

He said that the spike protein of the SARS-COV-2 virus has been screened and removed. By analyzing the genetic code of viral proteins, he has created a similar spike protein in his own laboratory. These proteins are less contagious and cannot reproduce by replication.

Zayner told that the vaccine candidate was designed with this artificially made viral protein. Once this vaccine would enter into the body, it would start the process of making antibodies. Stimulating B-cells and T-cells would produce antibodies in plasma.

Zayner told that this would be the first trial of this vaccine on rhesus monkeys. After the safety trial in the laboratory, the vaccine would be experimentally applied to the human body.

Patricia Zetler, a former attorney for the US Food and Drug Administration, said Zayner would try the first vaccine on himself and his team members. The vaccine will only be approved for a clinical trial if it is considered safe.

Shalini Gupta

About Shalini Gupta

Shalini Gupta is a teacher at New Delhi with multifarious talents. She has passion for reading, writing, drawing, sketching etc. simultaneously with her teaching job. presently she is writing for Bigumbrella.

View all posts by Shalini Gupta →

Leave a Reply

Your email address will not be published. Required fields are marked *

*